Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Nan Zhang, Yanliang Zhang, PhD, Xia Cao, MSc, Irina Krapf, MSc, Qingdong Mark Deng, Angel Wei, MD, Jerome B. Zeldis, MD PhD, Robert D. Knight, MD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 1942.

https://doi.org/10.1182/blood-2019-131892

Published: 2019

Journal Articles

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy

Srinivas Somanchi, PhD, Xuan Guo, PhD, Shuyang He, PhD, Rohit Mathur, PhD, Andrea Difiglia, BS, Hemlata Rana, MS, Weifang Ling, PhD, James Edinger, PhD, Gunnar F. Kaufmann, PhD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 2070.

https://doi.org/10.1182/blood-2019-129539

Published: 2019

Journal Articles

Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody

Xiao He, PhD, Yanliang Zhang, PhD, Yun Wei Lai, MSc, Stephanie Baguley, MSc, Yan Li, PhD, Xia Cao, MSc, Ying Yan, PhD, Ken Takeshita, MD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Gunnar F. Kaufmann, PhD

Blood (2019) 134 (Supplement_1): 4463.

https://doi.org/10.1182/blood-2019-131540

Published: 2019

Journal Articles

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Bei Bei Ding, PhD, John Dixon Gray, PhD, Irina Krapf, MSc, Yanliang Zhang, PhD, Nan Zhang, Qingdong Mark Deng, Angel Wei, MD, Robert D. Knight, MD, Jerome B. Zeldis, MD PhD, Gunnar F. Kaufmann, PhD, Henry Ji, PhD, Wenzhong Guo, PhD

Blood (2019) 134 (Supplement_1): 4444.

https://doi.org/10.1182/blood-2019-131586

Published: 2019

Journal Articles

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies

Kathy Karasiewicz, MSc, Shuyang He, PhD, Mary Ng, MSc, Kristina Tess, Weifang Ling, PhD, Gunnar F. Kaufmann, PhD, Jerome B. Zeldis, MD PhD, Henry Ji, PhD, Robert Hariri, MD PhD, Xiaokui Zhang, PhD

Blood (2019) 134 (Supplement_1): 3222.

https://doi.org/10.1182/blood-2019-130782

Published: 2019

Journal Articles

Pomalidomide Induces Expansion of Activated and Central Memory CD4+ and CD8+ T Cells in Vivo in Patients with and without HIV Infection

Mark N. Polizzotto, MBBS, FRACP, FRCPA, Irini Sereti, MD, Thomas S. Uldrick, MD MS, Kathleen M. Wyvill, RN, Stig M. R. Jensen, PhD, Amrit Singh, BSc, Stephen B. Kovacs, BSc, Karen O. Aleman, RN, Vickie Marshall, PhD, Denise Whitby, PhD, Frank Maldarelli, MD PhD, Seth M. Steinberg, PhD, Jerome B. Zeldis, MD PhD, Robert Yarchoan, MD

Blood (2014) 124 (21): 4128.

https://doi.org/10.1182/blood.V124.21.4128.4128

Published: 2014

Journal Articles

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Divya Nair, MD, Vaishali Sanchorawala, MD, Anthony C Shelton, RN, Salli A Fennessey, Kathleen T Finn, ANP, Martha Skinner, MD, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2012) 120 (21): 4084.

https://doi.org/10.1182/blood.V120.21.4084.4084

Published: 2012

Journal Articles

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Aleksandr Lazaryan, MD, MPH, PhD, Rachid Baz, MD, Mohamad A Hussein, Jr, MD, Paul Elson, ScD, Beth Faiman, CNP, Becky Habecker, Mary Ann Karam, RN, Janice Reed, RN, Kimberly Hamilton, RN, Kellie Bruening, Gordan Srkalovic, MD, PhD, Steven Andresen, DO, Matt Kalaycio, MD, John William Sweetenham, MD, FRCP, Ronald Sobecks, MD, Robert Dean, MD, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Frederic J. Reu, MD

Blood (2010) 116 (21): 1967.

https://doi.org/10.1182/blood.V116.21.1967.1967

Published: 2010

Journal Articles

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Umit Tapan, MD, David C Seldin, MD, PhD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, Vaishali Sanchorawala, MD

Blood (2010) 116 (21): 3021.

https://doi.org/10.1182/blood.V116.21.3021.3021

Published: 2010

Journal Articles

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

Vaishali Sanchorawala, MD, Kathleen T Finn, ANP, Salli Fennessey, CRA, Anthony C Shelton, RN, Jerome B. Zeldis, MD, PhD, David C Seldin, MD, PhD

Blood (2010) 116 (21): 3022.

https://doi.org/10.1182/blood.V116.21.3022.3022

Published: 2010

Journal Articles

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

Luhua Wang, MD, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Sattva Neelapu, MD, Felipe Samaniego, MD, Peter McLaughlin, MD, Barry Samuels, MD, Qing Yi, MD, PhD, Barbara Pro, MD, Michelle Fanale, M.D., Jatin Shah, MD, Anas Younes, MD, Neda Bell, Robert Knight, MD, Jerome B. Zeldis, MD, PhD, Fernando Cabanillas, MD, Larry Kwak, MD, PHD, Jorge Romaguera, MD

Blood (2009) 114 (22): 2719.

https://doi.org/10.1182/blood.V114.22.2719.2719

Published: 2009

Journal Articles

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Julie M. Vose, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Izidore S. Lossos, MD, Annette Ervin-Haynes, DO, Kenichi Takeshita, MD, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2570.

https://doi.org/10.1182/blood.V110.11.2570.2570

Published: 2007

Journal Articles

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Thomas E. Witzig, MD, Craig B. Reeder, MD, Jonathan Polikoff, MD, Naveed M. Chowhan, MD, Isaac Esseessee, MD, Richard Greenberg, MD, Hermant Patel, MD, Davood Vafai, MD, Peter H. Wiernik, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Myron Czuczman, MD

Blood (2007) 110 (11): 2572.

https://doi.org/10.1182/blood.V110.11.2572.2572

Published: 2007

Journal Articles

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Thomas E. Witzig, MD, Julie M. Vose, MD, Timothy D. Moore, MD, Craig B. Reeder, MD, Craig E. Cole, MD, Glen Justice, MD, Henry P. Kaplan, MD, Michael Voralia, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Peter H. Wiernik, MD

Blood (2007) 110 (11): 2560.

https://doi.org/10.1182/blood.V110.11.2560.2560

Published: 2007

Journal Articles

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Joseph M. Tuscano, MD, Izidore S. Lossos, MD, Glen Justice, MD, Julie M. Vose, MD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Dennis Pietronigro, PhD, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2563.

https://doi.org/10.1182/blood.V110.11.2563.2563

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Izidore S. Lossos, MD, Peter H. Wiernik, MD, Glen Justice, MD, Joseph M. Tuscano, MD, Craig E. Cole, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2564.

https://doi.org/10.1182/blood.V110.11.2564.2564

Published: 2007

Journal Articles

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Peter H. Wiernik, MD, Izidore S. Lossos, MD, Joseph M. Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Craig E. Cole, MD, Kyle McBride, MS, Kenton Wride, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD, PhD, Thomas M. Habermann, MD

Blood (2007) 110 (11): 2565.

https://doi.org/10.1182/blood.V110.11.2565.2565

Published: 2007

Journal Articles

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Peter H. Wiernik, MD, Izidore Lossos, MD, Joseph Tuscano, MD, Glen Justice, MD, Julie M. Vose, MD, Dennis Pietronigro, PhD, Kenichi Takeshita, MD, Annette Ervin-Haynes, DO, Jerome B. Zeldis, MD,PhD, Thomas M. Habermann, MD

Blood (2006) 108 (11): 531.

https://doi.org/10.1182/blood.V108.11.531.531

Published: 2006

Journal Articles

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Azra Raza, MD, James E. Reeves, MD, Eric J. Feldman, MD, H. Joachim Deeg, MD, Luke Dreisbach, MD, Charles A. Schiffer, MD, Jamile M. Shammo, MD, Virginia M. Klimek, MD, Peter L. Greenberg, MD, John M. Bennett, MD, Gordon W. DeWald, PhD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RN,C, Robert D. Knight, MD, Alan F. List, MD

Blood (2006) 108 (11): 250.

https://doi.org/10.1182/blood.V108.11.250.250

Published: 2006

Journal Articles

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

Alan F. List, MD, Gordon W. Dewald, PhD, John M. Bennett, MD, Aristoteles Giagounidis, MD, Azra Raza, MD, Eric J. Feldman, MD, Bayard L. Powell, MD, Peter L. Greenberg, MD, Stephen D. Nimer, MD, Jerome B. Zeldis, MD, PhD, Kenton Wride, MS, Michele Schmidt, RNC, Robert D. Knight, MD

Blood (2006) 108 (11): 251.

https://doi.org/10.1182/blood.V108.11.251.251

Published: 2006

NARROW

Development of an Allogeneic Anti-Bcma T Cell Therapy Utilizing a Novel Dimeric Antigen Receptor (DAR) Structure

Development of CD38 CAR Engineered Human Placental Hematopoietic Stem Cell Derived Natural Killer Cells (PNK-CAR38) As Allogeneic Cancer Immunotherapy

Preclinical Characterization of an ANTI-CD38/CD3 T CELL-Redirecting Bispecific Antibody

Development of a Genetically-Engineered Allogeneic Anti-CD38 T Cell Therapy Utilizing a Novel Antigen Receptor Structure

Preclinical Evaluation of Human Placental-Derived Allogeneic CD19 CAR-T Cells Against B Cell Malignancies

Pomalidomide Induces Expansion of Activated and Central Memory CD4+ and CD8+ T Cells in Vivo in Patients with and without HIV Infection

Lenalidomide and Dexamethasone in the Treatment of AL Amyloidosis: Final Results of A Phase II Trial

Mature Results of MM011: A Phase I/II Trial of Lenalidomide, Liposomal Doxorubicin, Dexamethasone, and Vincristine, Followed by Lenalidomide Maintenance (DVd-R) for Relapsed or Refractory Multiple Myeloma

Increases In B-Type Natriuretic Peptide (BNP) During Treatment with Lenalidomide In AL Amyloidosis

Lenalidomide Treatment In Patients with AL Amyloidosis Associated End-Stage Renal Disease and Dialysis

A Phase I/II Study of Lenalidomide in Combination with Rituximab in Relapsed/Refractory Mantle Cell Lymphoma.

High Response Rate to Lenalidomide in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma with Prior Stem Cell Transplant.

Initial Results from an International Study in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma To Confirm the Activity, Safety and Criteria for Predicting Response to Lenalidomide Monotherapy.

Results from a Phase II Study of Lenalidomide Oral Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Diffuse Large B-Cell Non-Hodgkin’s Lymphoma.

Lenalidomide Response in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma Is Related to Tumor Burden and Time from Rituximab Treatment.

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

Long Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome without Del 5q Cytogenetic Abnormalities.

Long-Term Clinical Benefit of Lenalidomide (Revlimid) Treatment in Patients with Myelodysplastic Syndrome and Chromosome Deletion 5q.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only